Autres langues Omeros Corporation

Actions

OMER

US6821431029

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 18:03:25 21/08/2026			Varia. 5j.	Varia. 1 janv.
19,28 ^USD	+3,52%		+11,55%	+11,64%

13/08	Omeros Corporation annonce la nomination de Joseph Schocken en tant qu'administrateur et membre du comité d'audit, avec effet au 12 août 2026	CI
13/08	Omeros renoue avec les bénéfices au deuxième trimestre ; le titre grimpe	MT

Autres langues

13/08	Omeros Corporation Announces Appointment of Joseph Schocken as Director and Audit Committee Member, Effective August 12, 2026
13/08	Omeros Swings to Q2 Adjusted Earnings; Shares up
12/08	Omeros: Q2 Earnings Snapshot
12/08	Tranche Update on Omeros Corporation's Equity Buyback Plan announced on December 1, 2025.
12/08	Tranche Update on Omeros Corporation's Equity Buyback Plan announced on December 1, 2025.
12/08	Earnings Flash (OMER) Omeros Corporation Reports Q2 Revenue $28.5M, vs. FactSet Est of $12.7M
12/08	Earnings Flash (OMER) Omeros Corporation Posts Q2 Adjusted EPS $0.02 per Share
12/08	Omeros Corporation Reports Second Quarter 2026 Financial Results
12/08	Omeros Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
10/08	Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
03/08	CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®
26/06	Omeros Corporation Provides Update On European Marketing Authorization Application For Narsoplimab In TA-TMA
26/06	Omeros to Seek EMA Review After Negative Opinion on Narsoplimab Marketing Application
26/06	Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
26/06	Top Premarket Decliners
15/06	Omeros Announces Webcast Details for Annual Meeting of Shareholders
13/05	Omeros Q1 Adjusted Loss Narrows
13/05	Omeros: Q1 Earnings Snapshot
13/05	Tranche Update on Omeros Corporation's Equity Buyback Plan announced on December 1, 2025.
13/05	Omeros Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026
13/05	Earnings Flash (OMER) Omeros Corporation Reports Q1 Revenue $9.9M, vs. FactSet Est of $4.2M
13/05	Earnings Flash (OMER) Omeros Corporation Posts Q1 Adjusted Loss $0.24 per Share, vs. FactSet Est of $-0.39
13/05	Omeros Corporation Reports First Quarter 2026 Financial Results
11/05	Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
20/04	Sagimet Biosciences Inc Announces Executive Changes, Effective April 20, 2026